Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluticasone propionate + albuterol sulfate (Teva Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
**DARI** is Teva's investigational fixed-dose, dual-action asthma rescue inhaler containing the inhaled corticosteroid fluticasone propionate and the short-acting beta2-adrenergic agonist albuterol sulfate. Delivered through Teva's breath-activated multidose dry-powder inhaler, it is intended to provide rapid bronchodilation from albuterol while concurrently treating airway inflammation through glucocorticoid-receptor activation by fluticasone. The program is being developed for reduction and prevention of asthma exacerbations in adult and pediatric populations, with Launch Therapeutics managing clinical-trial execution while Teva retains manufacturing, U.S. regulatory, and commercialization responsibilities. ([tevausa.com](https://www.tevausa.com/news-and-media/press-releases/clinical-collaboration-agreement-between-teva-and-launch-therapeutics-to-accelerate-development-of-dual-a/))
- Other names
- DARIDual-Action Asthma Rescue Inhaler
02
Targets
ADRB2 (β2)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on fluticasone propionate + albuterol sulfate (Teva Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluticasone propionate + albuterol sulfate (Teva Pharmaceutical).